PR Newswire
10x Genomics’ ATAC-Seq patents found valid and infringed
PLEASANTON, Calif.
, March 3, 2025 /PRNewswire/ — 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, 2025, in the United States District Court for the District of Delaware, Parse agreed – a week before trial was to start – to a worldwide permanent injunction that prevents it from making, using, selling or offering for sale its planned ATAC and ATAC-Multiome Single Cell products. As part of this consent agreement, Parse admitted that 10x’s ATAC-seq patents are valid, enforceable and infringed by Parse’s use of ATAC-seq methods and compositions.
“This development further validates the strength of our broad patent portfolio, which helps protect and preserve the world-class innovation engine at 10x,” said Eric S. Whitaker, Chief Legal Officer of 10x Genomics. “We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal.”
The company’s litigation against Parse’s gene expression products remains ongoing, with additional asserted patents under appeal. Following entry of the injunction, the trial scheduled for March 2025 concerning 10x’s remaining patent infringement claims against Parse has been stayed pending those appeals.
10x Genomics is committed to defending its intellectual property and investing in groundbreaking technologies that empower researchers worldwide.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X (Twitter), Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the “safe harbor” provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding litigation and potential outcomes of litigation. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics’ financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the “SEC”) from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics’ views as of any date subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
Contacts
Investors: [email protected]
Media: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-secures-injunction-against-parse-biosciences-planned-atac-products-302390537.html
SOURCE 10x Genomics, Inc
